Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASK0315
- Development stage
- Unknown
- Lead developer
- Jiangsu Aosaikang Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
ASK0315 is a monoclonal antibody being developed by Jiangsu Aosaikang Pharmaceutical that targets interleukin-17 (IL-17). IL-17 is a pro-inflammatory cytokine that plays a central role in the pathogenesis of various inflammatory and autoimmune conditions, including inflammatory bowel disease (IBD). By binding to IL-17 and preventing its interaction with its receptor, ASK0315 inhibits the downstream inflammatory cascades and the recruitment of inflammatory cells that contribute to tissue damage in the gastrointestinal tract. The drug is currently in Phase 2 clinical development specifically for the treatment of moderate-to-severe Crohn's disease.
02
Targets
Beyond the preview
Go deeper on ASK0315.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASK0315.